

## 1. Identifying information

Firstname: Mike

Surname: Sharland

ESCMID Membership ID: 61404

Email: msharland@sgul.ac.uk

## 2. ESCMID-related functions

### Study Groups

—

### Committees and subcommittees

AMR Action Subcommittee

### ESCMID Executive Committee

None

## 3. Organizational roles

—

## 4. Financial declarations

### 4.1 Primary employments

Employer: City St George's, University of London

Position: Professor of Paediatric Infectious Diseases

## 4.2 Other financial relationships and/or income

---

## 5. Additional comments

I am the chief investigator of the PediCAP trial, an EU-funded study that compares amoxicillin to amoxicillin-clavulanic acid in children admitted to hospital with severe pneumonia in Africa. Sandoz provided the IMP for the trial, which included amoxicillin-clavulanic dispersible tablets for children. The trial completed recruitment in 2024. I am the chief investigator of the NeoSEP1 trial, which is funded by the Global Antibiotic Research and Development Partnership (GARDP) and EDCTP, which compares novel combinations of generic antibiotics to treat neonatal sepsis. The antibiotics under study include fosfomycin, provided by InfectoPharm, and flomoxef, provided by Shionogi. The trial commenced recruitment in 2023. I am a clinical advisor to GARDP. The Centre for Neonatal and Paediatric Infection at City St George's, University of London received academic funding from GARDP for the design and conduct of clinical studies of antibiotics in the GARDP program. I receive no personal financial support from GARDP. I was the Chair of the WHO EML Antibiotic Working Group. I am the lead for the Antibiotic Policy Group at City St George's University of London, which is now a WHO Collaborating Centre for Antimicrobial Stewardship and Policy.

## 6. Last upload date

2025-11-13